P3.02b-087 Dose Escalation Study of CDDP plus PEM with Erlotinib and Bev Followed by PEM with Erlotinib and Bev for Non-SQ NSCLC Harboring EGFR MutationsGefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for advanced non-small cell ...
P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)doi:10.1016/j.jtho.2018.08.589Harada, T.Udagawa, H.Sugiyama, E.Atagi, S.Koyama, R.Watanabe, S.
P3.01-90 A Phase II Study Evaluating Continuation of EGFR-TKIs Beyond Progressive Disease Followed by the Addition of CDDP+PEM+Bevdoi:10.1016/j.jtho.2018.08.1650S. ShojiS. WatanabeK. NozakiK. IchikawaT. KikuchiJournal of Thoracic Oncology...